GMED
GLOBUS MEDICAL INC
Overview
Globus Medical designs and manufactures implantable medical devices, biologics, surgical instruments, robotic navigation systems, and neuromodulation therapies for treating musculoskeletal disorders of the spine, orthopedic trauma, hip and knee joints, and chronic pain.
GLOBUS MEDICAL INC is a Healthcare company operating in Medical Devices with a $10.75B market cap.
Most recent reported earnings: Q2 FY2026 (Aug 5, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-0730 Q&A exchanges
- Q4 FY2025Earnings2026-02-2419 Q&A exchanges
- Q3 FY2025Earnings2025-11-0617 Q&A exchanges
- Q2 FY2025Earnings2025-08-0818 Q&A exchanges
- Q1 FY2025Earnings2025-05-0823 Q&A exchanges
- Q4 FY2024Earnings2025-02-2041 Q&A exchanges
- Q3 FY2024Earnings2024-11-0534 Q&A exchanges
- Q2 FY2024Earnings2024-08-0637 Q&A exchanges
- Q1 FY2024Earnings2024-05-0720 Q&A exchanges
- Q4 FY2023Earnings2024-02-2027 Q&A exchanges
- Q3 FY2023Earnings2023-11-0727 Q&A exchanges
- Q2 FY2023Earnings2023-08-0311 Q&A exchanges
- Q1 FY2023Earnings2023-05-0423 Q&A exchanges
- Q4 FY2022Earnings2023-02-2135 Q&A exchanges
- Q3 FY2022Earnings2022-11-0819 Q&A exchanges
- Q2 FY2022Earnings2022-08-0427 Q&A exchanges
- Q1 FY2022Earnings2022-05-1021 Q&A exchanges
- Q4 FY2021Earnings2022-02-1727 Q&A exchanges
- Q3 FY2021Earnings2021-11-0411 Q&A exchanges
- Q2 FY2021Earnings2021-08-0440 Q&A exchanges
- Q1 FY2021Earnings2021-05-0428 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-05EPS— vs $1.12—Rev— vs ——EODHD
- Q1 FY20262026-05-07EPS$1.12 vs $0.92+21.7%Rev$759.9M vs ——EODHD
- Q4 FY20252026-02-24EPS$1.28 vs $1.15+11.0%Rev$826.4M vs ——EODHD
- Q3 FY20252025-11-03EPS$1.18 vs $0.77+53.3%Rev$769.0M vs ——EODHD
- Q2 FY20252025-08-06EPS$0.86 vs $0.75+14.7%Rev$745.3M vs ——EODHD
- Q1 FY20252025-05-07EPS$0.68 vs $0.74-8.1%Rev$598.1M vs ——EODHD
- Q4 FY20242025-02-17EPS$0.84 vs $0.75+12.2%Rev$657.3M vs ——EODHD
- Q3 FY20242024-11-04EPS$0.83 vs $0.65+27.7%Rev$625.7M vs ——EODHD
- Q2 FY20242024-08-05EPS$0.75 vs $0.68+10.3%Rev$629.7M vs ——EODHD
- Q1 FY20242024-05-06EPS$0.72 vs $0.57+26.3%Rev$606.7M vs ——EODHD
- Q4 FY20232024-02-19EPS$0.60 vs $0.61-1.6%Rev$616.5M vs ——EODHD
- Q3 FY20232023-11-06EPS$0.57 vs $0.570.0%Rev$383.6M vs ——EODHD
- Q2 FY20232023-08-02EPS$0.63 vs $0.59+6.8%Rev$291.6M vs ——EODHD
- Q1 FY20232023-05-03EPS$0.53 vs $0.51+3.9%Rev$276.7M vs ——EODHD
- Q4 FY20222023-02-20EPS$0.59 vs $0.56+5.4%Rev$274.5M vs ——EODHD
- Q3 FY20222022-11-07EPS$0.50 vs $0.52-3.9%Rev$254.1M vs ——EODHD
- Q2 FY20222022-08-03EPS$0.56 vs $0.53+5.7%Rev$263.6M vs ——EODHD
- Q1 FY20222022-05-09EPS$0.42 vs $0.47-10.6%Rev$230.5M vs ——EODHD
- Q4 FY20212022-02-16EPS$0.49 vs $0.47+4.3%Rev$250.0M vs ——EODHD
- Q3 FY20212021-11-03EPS$0.50 vs $0.45+11.1%Rev$229.7M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-05 | — | $1.12 | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-05-07 | $1.12 | $0.92 | +21.7% | $759.9M | — | — | EODHD |
| Q4 FY2025 | 2026-02-24 | $1.28 | $1.15 | +11.0% | $826.4M | — | — | EODHD |
| Q3 FY2025 | 2025-11-03 | $1.18 | $0.77 | +53.3% | $769.0M | — | — | EODHD |
| Q2 FY2025 | 2025-08-06 | $0.86 | $0.75 | +14.7% | $745.3M | — | — | EODHD |
| Q1 FY2025 | 2025-05-07 | $0.68 | $0.74 | -8.1% | $598.1M | — | — | EODHD |
| Q4 FY2024 | 2025-02-17 | $0.84 | $0.75 | +12.2% | $657.3M | — | — | EODHD |
| Q3 FY2024 | 2024-11-04 | $0.83 | $0.65 | +27.7% | $625.7M | — | — | EODHD |
| Q2 FY2024 | 2024-08-05 | $0.75 | $0.68 | +10.3% | $629.7M | — | — | EODHD |
| Q1 FY2024 | 2024-05-06 | $0.72 | $0.57 | +26.3% | $606.7M | — | — | EODHD |
| Q4 FY2023 | 2024-02-19 | $0.60 | $0.61 | -1.6% | $616.5M | — | — | EODHD |
| Q3 FY2023 | 2023-11-06 | $0.57 | $0.57 | 0.0% | $383.6M | — | — | EODHD |
| Q2 FY2023 | 2023-08-02 | $0.63 | $0.59 | +6.8% | $291.6M | — | — | EODHD |
| Q1 FY2023 | 2023-05-03 | $0.53 | $0.51 | +3.9% | $276.7M | — | — | EODHD |
| Q4 FY2022 | 2023-02-20 | $0.59 | $0.56 | +5.4% | $274.5M | — | — | EODHD |
| Q3 FY2022 | 2022-11-07 | $0.50 | $0.52 | -3.9% | $254.1M | — | — | EODHD |
| Q2 FY2022 | 2022-08-03 | $0.56 | $0.53 | +5.7% | $263.6M | — | — | EODHD |
| Q1 FY2022 | 2022-05-09 | $0.42 | $0.47 | -10.6% | $230.5M | — | — | EODHD |
| Q4 FY2021 | 2022-02-16 | $0.49 | $0.47 | +4.3% | $250.0M | — | — | EODHD |
| Q3 FY2021 | 2021-11-03 | $0.50 | $0.45 | +11.1% | $229.7M | — | — | EODHD |
Source: EODHD. GMED reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks GMED's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $1.16 | $1.49 | -22.2% | +0.9% | +0.2% |
| Q4 FY2026 | $1.23 | $1.67 | -26.6% | -0.8% | -1.7% |
| Q3 FY2026 | $1.06 | $1.50 | -29.1% | -2.7% | -4.0% |
| Q2 FY2026 | $1.24 | $1.66 | -25.2% | +5.7% | +3.5% |
| Q1 FY2025 | $1.21 | $1.67 | -27.7% | +0.3% | +0.1% |
| Q4 FY2025 | $1.35 | $1.79 | -24.8% | +5.0% | +3.3% |
| Q3 FY2025 | $1.22 | $1.63 | -25.1% | +0.1% | +0.1% |
| Q2 FY2025 | $1.35 | $1.82 | -25.7% | -1.8% | +0.3% |
| Q1 FY2024 | $1.29 | $1.77 | -27.1% | -1.0% | -2.1% |
| Q4 FY2024 | $1.21 | $1.77 | -31.4% | -3.8% | -4.4% |
Guidance change history
Sample- Q1 FY2026Lowered2026-04-15
- Q4 FY2026Lowered2026-13-15
- Q3 FY2026Lowered2026-10-15
- Q2 FY2026Lowered2026-07-15
- Q1 FY2025Lowered2025-04-15
- Q4 FY2025Lowered2025-13-15
- Q3 FY2025Lowered2025-10-15
- Q2 FY2025Lowered2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Keith W PfeilCEO11 mo21 callsCurrentSample
CEO since 2025 • 2/4 beats (50%) • last guidance raise Q1 FY2026
- Kyle KlineCFO11 mo4 callsCurrentSample
CFO since 2025 • 2/4 beats (50%) • last call held guidance Q2 FY2026
- Kelly HullerEVP, GC, Corporate Secretary5 mo1 callCurrentSample
DIVISION_HEAD since 2026 • 1/2 beats (50%) • last guidance raise Q2 FY2026
- David C PaulExecutive Chairman1 yr 5 mo1 callCurrentSample
OTHER since 2025 • 3/4 beats (75%) • last guidance cut Q2 FY2026
- Daniel T ScavillaCEO0 mo16 callsFormerSample
CEO since 2025 • 2/4 beats (50%) • last guidance raise Q2 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for GMED.
$ curl https://api.spokenalpha.com/v1/companies/GMEDFAQ
Frequently asked about GMED
Where can I find GLOBUS MEDICAL INC's (GMED) earnings call transcripts?
Spoken Alpha indexes GMED's earnings call transcripts at https://spokenalpha.com/companies/GMED. Each call links to attributed speakers and parsed analyst Q&A. GLOBUS MEDICAL INC's own investor relations page is at https://www.investors.globusmedical.com/.
When was GLOBUS MEDICAL INC's most recent earnings call?
GLOBUS MEDICAL INC (GMED) held its most recent earnings call on 2026-05-07, covering fiscal Q1 2026.
What sector is GMED in?
GLOBUS MEDICAL INC (GMED) operates in the Healthcare sector (Medical Devices industry).